Drug Landscape ›
Paracetamol 1 g ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 19 April 2025 – 19 April 2026
Total reports: 11
Most-reported reactions
Pyrexia — 2 reports (18.18%) Abdominal Pain — 1 report (9.09%) Abdominal Pain Upper — 1 report (9.09%) Acute Kidney Injury — 1 report (9.09%) Arthralgia — 1 report (9.09%) Blood Chloride Decreased — 1 report (9.09%) Blood Potassium Increased — 1 report (9.09%) Blood Sodium Decreased — 1 report (9.09%) Colitis Ischaemic — 1 report (9.09%) Condition Aggravated — 1 report (9.09%)
Source database →
Paracetamol 1 g in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Paracetamol 1 g approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Paracetamol 1 g in United States?
Rigshospitalet, Denmark is the originator. The local marketing authorisation holder may differ — check the official source linked above.